Inhaler

WHO WE ARE

Respiratory drug delivery

Mother Child and Inhaler

WHO WE ARE

Respiratory drug delivery

Carclo supports the development and manufacture of next-generation respiratory drug delivery components and devices, from early-stage feasibility through to high-volume production.

What we make

Our work includes concept development, device architecture exploration, material selection, prototyping and scalable manufacturing solutions for:

  • Pressurised metered dose inhaler (pMDI) components
  • Dry powder inhaler (DPI) housings and mechanisms
  • Dose counters and integrated functional components
  • Human-factor-focused delivery concepts
  • Sustainable design solutions

Across the respiratory category, our goal is the creation of inhaler solutions that deliver performance, safety and sustainability without compromise.

  • Processes


    Injection moulding, CNC machining, polishing, optical coating, assembly, and clean-pack handling.

  • Parts envelope

    From micro-scale optical components to large-format moulded lenses and assemblies.

  • Tolerances

    Optical and mechanical tolerances verified to meet customer and application requirements.

  • Surface Finish

    Precision-polished or moulded finishes for optimal clarity, transmission, and performance.

  • Documentation

    Full traceability and certification available, including CoC, inspection reports, and material data.

  • Inspection

    Automated and manual inspection to ensure dimensional accuracy and optical quality.

  • MOOs

    Available on request for specific product families and validation projects.

How we make it

Respiratory conditions are among the most common chronic health challenges worldwide. Device usability, reliability and sustainability directly influence patient outcomes.

  • Carclo’s role in respiratory drug delivery matters because we:
  • Support accelerated device development and improve performance
  • Reduce manufacturing risk through early production-representative prototypes
  • Bring deep polymer expertise to address material and environmental challenges
  • Support the global push toward more sustainable inhaler technologies
  • Enable better patient experiences through intuitive, stable and consistent device architectures
  • Provide a scalable path from concept to full cleanroom production
Factory floor

Recent investments

Recent targeted investments strengthen Carclo’s capabilities in the field of respiratory drug delivery:

Background 2

  • Formation of the LifeTech Solutions innovation stream, enabling proprietary respiratory concepts

  • Expansion of cleanroom capacity for medical-class device components.

  • Acquisition of all-electric injection moulding platforms offering the precision required for inhaler geometries.

  • Development of production-intent prototyping via C-Mould, enabling faster design cycles and functional testing.

  • Enhanced materials analysis to support long-term performance.

  • Automation partnerships to support future device assembly and testing solutions.

  • Sustainability and polymer substitution initiatives aligned with global environmental expectations for respiratory devices.

Materials

Respiratory drug delivery places specific demands on materials - particularly stiffness, impact strength, chemical resistance, compatibility with propellants and dimensional stability under stress.

We work with a broad range of inhaler-relevant polymers, including sustainable alternatives such as mass-balance and biogenic carbon options.

Typical programmes

Respiratory projects integrate cross-functional testing - airflow, actuation force, leak integrity, cycling studies - supported by our materials and manufacturing expertise.

Why it matters

Respiratory conditions are among the most common chronic health challenges worldwide. Device usability, reliability and sustainability directly influence patient outcomes.

Carclo’s role in respiratory drug delivery matters because we:

  • Support accelerated device development and improve performance.
  • Reduce manufacturing risk through early production-representative prototypes.
  • Bring deep polymer expertise to address material and environmental challenges.
  • Support the global push toward more sustainable inhaler technologies.
  • Enable better patient experiences through intuitive, stable and consistent device architectures.
  • Provide a scalable path from concept to full cleanroom production.
Lungs